Insight into the therapeutic effects of artesunate in relieving metabolic‐associated steatohepatitis from transcriptomic and lipidomics analyses
Journal of Digestive Diseases · 2024
DOI: 10.1111/1751-2980.13311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Digestive Diseases, 2024. Verfasst von Jing Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Artesunate, Lipid Metabolism, Transcriptome, Lipidomics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Star Program of Shanghai Jiao Tong University, SJTU Trans-med Awards Research, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
Artesunate (ART) is a water‐soluble derivative of artemisinin, which has shown anti‐inflammatory, anti‐tumor, and immunomodulating effects. We aimed to investigate the potential therapeutic effects and mechanisms of ART in metabolic dysfunction‐associated steatohepatitis (MASH).
Methods
The mice were randomly divided into the control group, high‐fat, high‐cholesterol diet‐induced MASH group, and the MASH treated with ART (30 mg/kg once daily) group. Liver enzymes, lipids, and histological features were compared among groups. The molecular mechanisms were studied by transcriptomic and lipidomics analyses of liver tissues.
Results
The mice of the MASH group had significantly increased hepatic fat deposition and inflammation in terms of biochemical indicators and pathological manifestations than the control group. The ART‐treated group had improved plasma liver enzymes and hepatic cholesterol, especially at week 4 of intervention ( p < 0.05). A total of 513 differentially expressed genes and 59 differentially expressed lipids were identified in the MASH group and the MASH+ART group. Gene Ontology analysis and Kyoto Encyclopedia of Genes and Genomes pathway enrichment test showed that ART regulated glycerolipid metabolism pathway and enhanced fatty acid degradation. Peroxisome proliferator‐activated receptor (PPAR)‐α acted as a key transcription factor in the treatment of MASH with ART, which was confirmed by cell experiment.
Conclusions
ART significantly improved fat deposition and inflammatory manifestations in MASH mice, with potential therapeutic effects. The mechanism of artemisinin treatment for MASH may involve extensive regulation of downstream genes by upstream transcription factors, such as PPAR‐α, to restore hepatic lipid homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai, China.
- Department of Gastroenterology, Ningbo No. 2 Hospital, Ningbo, Zhejiang Province, China.
ORCID-Profile: Yi Wen Shi
Förderung
- Star Program of Shanghai Jiao Tong University
- SJTU Trans-med Awards Research
- National Natural Science Foundation of China
Zitieren
APA
Yang, J., Huang, L. J., Ren, T. Y., Zeng, J., Shi, Y. W., & Fan, J. G. (2024). Insight into the therapeutic effects of artesunate in relieving metabolic‐associated steatohepatitis from transcriptomic and lipidomics analyses. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13311
Vancouver
Yang J, Huang LJ, Ren TY, Zeng J, Shi YW, Fan JG. Insight into the therapeutic effects of artesunate in relieving metabolic‐associated steatohepatitis from transcriptomic and lipidomics analyses. Journal of Digestive Diseases. 2024. doi:10.1111/1751-2980.13311
BibTeX
@article{Yang2024,
author = {Yang, Jing and Huang, Lei Jie and Ren, Tian Yi and Zeng, Jing and Shi, Yi Wen and Fan, Jian Gao},
title = {Insight into the therapeutic effects of artesunate in relieving metabolic‐associated steatohepatitis from transcriptomic and lipidomics analyses},
journal = {Journal of Digestive Diseases},
year = {2024},
doi = {10.1111/1751-2980.13311}
}
EUVIMED